Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Advent International in connection with its acquisition of a minority interest in Medius
Mandate

Vinge has advised Advent International in connection with its acquisition of a minority interest in Medius

March 17, 2022 Employment and Benefits Banking and Finance M&A Commercial Agreements Intellectual Property

Medius is a global leader in AP automation, payments, sourcing and procurement. The company’s suite of products and services automate the process of receiving, handling, approving, and paying an invoice, and simplify the onboarding and managing of vendors.

Vinge’s team consisted primarily of Christina Kokko, Ulrich Ziche, Isabelle Wållgren, Eléonore Friberg and Elias Bohlin (M&A), Josefine Lanker (Banking & Finance), Mika Jordan (Commercial Agreements), Fredrika Hjelmberg and Karolina Fuhrman (IT/GDPR), Michael Montner (IP), and Veronika Garemark (Employment).

More information on the transaction can be found here. https://www.adventinternational.com/advent-international-to-acquire-minority-stake-in-spend-management-leader-medius/ 

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026